SCHEMBL215596

SCHEMBL215596

Cc1cccc(N(C(=O)c2nc[nH]c2C(N)=O)c2nc3ccccc3[nH]2)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.38
TP53 P04637 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
GAA P10253 1/20 0.35
HTT P42858 2/20 0.34
HPGD P15428 1/20 0.34
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPT P10636 2/20 0.33
FPR1 P21462 1/20 0.33
PAX8 Q06710 1/20 0.33
CYP3A4 P08684 1/20 0.33
CDK1 P06493 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL214715 0.93 POLB (0.40) POLBNPC1RAB9ASMN1; SMN2GAA
SCHEMBL214451 0.91 POLB (0.37) POLBNPC1RAB9ASMN1; SMN2GAA
SCHEMBL213504 0.86 POLB (0.38) POLBNPC1RAB9ASMN1; SMN2GAA
SCHEMBL215645 0.86 POLB (0.37) POLBRAB9AHTTHPGDLMNA
SCHEMBL217227 0.86 POLB (0.37) POLBTP53NPC1RAB9ASMN1; SMN2
SCHEMBL216492 0.86 POLB (0.37) POLBTP53NPC1RAB9ASMN1; SMN2
SCHEMBL214873 0.85 LMNA (0.39) POLBNPC1RAB9ASMN1; SMN2GAA
SCHEMBL215369 0.85 POLB (0.41) POLBNPC1RAB9ASMN1; SMN2HTT
SCHEMBL214647 0.85 POLB (0.38) POLBNPC1RAB9AHTTHPGD
SCHEMBL216733 0.85 POLB (0.37) POLBNPC1RAB9ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 POLB 3464/4885TP53 1743/4885NPC1 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.